Fig. 5
From: Dual inhibition of αvβ6 and αvβ1 reduces fibrogenesis in lung tissue explants from patients with IPF
Comparison of plasma PLN-74809 concentrations (red) with pSmad3/Smad3 ratio (blue) in A BAL cells and B lung tissue from bleomycin-challenged mice. C Comparison of plasma PLN-74809 concentrations and pSmad2/Smad2 ratio in BAL cells from healthy mice. D Comparison of plasma PLN-74809 concentrations and pSmad3/Smad3 ratio in lung tissue from healthy mice. Bleomycin-challenged mice received three oral, 250 mg/kg doses BID starting 13 days post-challenge, with lung tissue and BAL cells collected 14 days post-challenge at 2, 4, 8, and 16 h post-dose (n = 2 per group). Healthy mice received continuous infusion of PLN-74809 (1, 3, 10, 30, or 100 mg/kg/day) via osmotic minipump. BAL: Bronchoalveolar lavage; BID: twice daily; conc: concentration; PD: pharmacodynamics; PK: pharmacokinetics; pSmad2: phosphorylated Smad2; pSmad3: phosphorylated Smad3; TGF-β: transforming growth factor-β